ArticlePloS one2025
The disease burden of gout in Asian countries and regions from 1990 to 2021, risk factors and forecast analysis: A systematic study of Asian disease burden in 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Osteoarthritis: Epidemiology, Diagnosis, and Treatment.MedComm · 2026Review
- Epidemiological trends and burden of gout in China and the European Union: a GBD 2023 and Mendelian randomization study.Clinical rheumatology · 2026Article
- Article
- Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUse the Global Burden of Disease (GBD) database to obtain gout's disease burden indicators, risk factors, 1990-2021 data in Asian countries/regions and 2050 forecast data for gout prevention and control basis.
methodsCollect gout prevalence, incidence etc. from global burden of disease data in Asia, stratified by gender and age, analyze with statistical charts. Use Joinpoint regression model for trend analysis. Predict 2050 East Asia incidence rate with Bayesian Age-Period-Cohort (BAPC) model.
results1990 - 2021, Age-standardized Prevalence Rate (ASPR) and Age-standardized Incidence Rate (ASIR) rose globally, in Asia and SDI regions. East Asia's incidence rose fast. Men's ASPR is nearly three times that of women. 55-59 - year - olds have the highest incidence rate in 2021. High BMI patients are common, and low proportion of kidney dysfunction impairment. East Asia's ASIR will rise by 2050 but slower.
conclusionGout's disease burden rose in Asia 1990-2021. Prevalence and incidence vary by country/region, especially in East Asia. Men's prevalence is higher. 55-59 - year - olds have the highest prevalence. In Asia's developed countries, prevalence and incidence are above the global average in 2021. High BMI and kidney dysfunction impairment are key risk factors. These findings necessitate preventive strategies, enhanced cooperation in prevention and control management, public awareness campaigns, and early treatment interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.